Business
‘Groundbreaking approach’: Imugene deal looks to smash solid tumours – Sydney Morning Herald
The $1.5 billion biotech will work with Nasdaq-listed firm Celularity in hopes of cracking the mystery of how to target tough…
Imugene, the cancer treatment maker chaired by biotech veteran Paul Hopper, is banking on a partnership with Nasdaq-listed biotech Celularity to unlock a revolutionary treatment that will obliterate solid tumours.
The Sydney-based company, which has seen…
Continue Reading
-
Business15 hours agoWarning! These ASX 200 shares were just downgraded
-
Business13 hours ago2 monthly payers you’ll want to own in 2025 and beyond
-
General24 hours agoTelco Exetel fined $694K after scammers bypass verification processes, access bank accounts
-
General23 hours agoSergio Perez and Valtteri Bottas to return to Formula 1 with Cadillac